In an effort to address these limitations, this report examined RCTs of individually-delivered empirically supported treatments (SRI or CBT) to determine their efficacy in reducing obsessive-compulsive symptom severity and to identify the risk ratios (RR) of experiencing a clinically meaningful response to treatment and symptom/diagnostic remission. Analyses across these three outcomes can provide clinicians with important probabilistic treatment response and symptom/diagnostic remission rates to aid parents and clinicians in the selection of empirically-supported monotherapies. Based on factors purported to impact treatment efficacy, treatment response, and symptom/diagnostic remission among CBT and SRI trials,[38; 42–45] this report examined the following putative treatment moderators: participant age; comorbidity (CTD, ADHD, depressive disorders, and anxiety disorders); baseline OCD symptom severity; medication status (for CBT trials); therapeutic contact (for CBT trials); attrition; treatment subtype; and methodological quality. Based on findings from individual RCTs, we had several hypotheses. First, we hypothesized that CBT would outperform comparison conditions. Second we hypothesized that SRIs would outperform comparison conditions. Finally, given the variable findings across moderators in individual RCTs, the association between purported moderators and treatment effects were explored across
